Abstract Details

Title Prevalence and Clinical Correlation of Left Ventricular Systolic Dysfunction in African American Population with Ischemic Stroke

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P02 - (-)

Poster/Presentation
Number 044

Objective

Background BACKGROUND: LVSD is a known risk factor (RF) for IS. Embolic strokes mostly originate from the heart with morbidity and mortality depending on location of stroke. AA population is in the high risk category for stroke but there is paucity of data regarding LVSD as a RF for IS in this population.

Design/Methods DESIGN/METHODS: Retrospective chart analysis was done on all diagnosed IS patients from January 2010 to March 2012. Transthoracic 2-dimensional echocardiography was used to assess LV systolic function and categorized as normal (>50%), mildly (41% to 50%), moderately (31% to 40%) or severely (<30%) abnormal. Computerized tomography, magnetic resonance (MR) imaging, MR angiography and ultrasound findings were utilized for data collection. Patients with atrial fibrillation were excluded.

Results RESULTS: 147 total IS patients were identified. Normal ejection fraction (EF) was present in 114/147 patients (77.55%) and abnormal EF in 33/147 (22.45%) - (mild -9/147, moderate -8/147, severe -16/147). In mildly reduced EF group, smoking was the most common RF, stroke was mostly on right side and most frequent location was cerebellum. In moderately reduced EF group, hypertension (HTN) was the most common RF, stroke was mostly bilateral and most frequent location was fronto-parietal. In severely reduced EF group, HTN was the most common RF, stroke was mostly bilateral and most frequent location was frontal lobe. Complete internal carotid occlusion was present in one patient and intracranial stenosis was present in two patients within the abnormal ejection fraction group.

Conclusions CONCLUSIONS: In this study the prevalence of LVSD in AA population with ischemic stroke was 22.45%. Among these, there was correlation between location of stroke and severity of LVSD. However prospective randomized studies are needed to validate our results.

Authors/Disclosures
Saravana K. Devulapalli, MD PRESENTER	No disclosure on file
Shariff S. Dunlap, MD (Anne Arundel Medical Center)	No disclosure on file
	No disclosure on file
Stephen H. Cockburn, MD (Virginia Commonwealth University Health System)	No disclosure on file
Mohankumar Kurukumbi, MD	Dr. Kurukumbi has nothing to disclose.
Annapurni J. Trouth, MD, FAAN (Howard Univ Hosp - Neurology Retired)	No disclosure on file
Linda P. Lowes, PT PhD	The institution of Ms. Lowes has received research support from Sarepta Therapeutics.

��ɫ��

��ɫ��